返回

Ingenia expands TIE2 drug platform into kidney disease with U.S. trial

正在验证中
  • Ingenia filed a U.S. application to test IGT-303 in chronic kidney disease.
  • The planned Phase 1/2a trial will enroll 94 participants across five U.S. sites.
  • MSD began global Phase 3 testing of MK-8748 after acquiring EyeBio.
本网站上的信息是使用AI生成的，我们无法保证其准确性。 请仅作为参考信息使用。